Pivlaz^® is a potent, selective endothelin A (ETA) receptor antagonist indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage (aSAH). Pivlaz^® is commercially available in Japan for cerebral vasospasm following a successful launch in April 2022. Sosei Heptares has the Japanese and APAC (ex-China) rights for Pivlaz^®.